Hyperion Cuts Its Losses After Andromeda Deception
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech revealed that its recently closed acquisition was conducted under false pretenses and that Andromeda employees had been manipulating clinical trial data for the late-stage type 1 diabetes drug.
You may also be interested in...
Hyperion Pricing On Ravicti Will Test Premium For Convenience In Orphan Market
Ravicti’s price tag is $250,000 to $290,000 per year while the upper WAC price for Valeant’s competing product Buphenyl is roughly $240,000 at the maximum dose; Hyperion has option to acquire Buphenyl.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.